Shea Wihlborg

Shea Wihlborg, a Multiomics Research Analyst at ARK Invest with a PhD in biochemistry, discusses the FDA's controversial halt of a Duchenne muscular dystrophy treatment. The conversation dives into how AI is revolutionizing drug discovery and clinical trials, paving the way for innovative gene therapies. Shea shares insights on potential regulatory changes and their impact on the biotech industry, alongside a look at how technologies like CRISPR could transform treatments for both rare and common diseases.